Featured Research

from universities, journals, and other organizations

Dual action polyclonal antibody may offer more effective, safer protection against osteoporosis

Date:
August 20, 2012
Source:
Mount Sinai Medical Center
Summary:
A new study suggests that a polyclonal antibody that blocks follicle-stimulating hormone (FSH) in mice without ovaries might offer a more effective way to prevent or arrest osteoporosis than currently available treatments.

A new study suggests that a polyclonal antibody that blocks follicle-stimulating hormone (FSH) in mice without ovaries might offer a more effective way to prevent or arrest osteoporosis than currently available treatments.

Related Articles


The study used a mouse model of menopause to show that an injection of a polyclonal antipeptide antibody enhances bone regeneration by simultaneously slowing bone destruction and building bone, say researchers at the Mount Sinai School of Medicine, New York. In addition, the monoclonal antibody is likely to be safer because it is cleared from the blood and is not retained in bone.

Results from the study are published online August 20 in the journal Proceedings of the National Academy of Sciences.

"Bone loss in women begins very early, at least two to three years before a woman's last period and within eight to ten years, a woman will lose 50% of her lifetime bone loss," says the study's senior investigator, Mone Zaidi, MD, Professor of Medicine and of Structural and Chemical Biology, at Mount Sinai School of Medicine in New York." It occurs painlessly, without notice up to a point where women fracture."

Zaidi, who is director, of the Mount Sinai Bone Program, at Mount Sinai School of Medicine, New York, is the senior investigator of the research that developed the polyclonal antipeptide antibody to FSH and tested it in mice whose ovaries were removed. Peptides are short chains of amino acids, and the FSH antibody is a highly specific antibody.

"A few years ago, we showed that FSH [follicle stimulating hormone] directly regulates bone by bypassing the estrogen axis," says Zaidi. FSH rises early in menopause, stimulates bone removal and negatively regulates bone formation. "By blocking FSH with the FSH-specific polyclonal antibody, we were able to block bone resorption by osteoclasts [cells that break down bone] and stimulate bone formation through osteoblasts cells [cells that build bone]."

Zaidi summed up the research team's goal: "Our aim is to find a way to prevent osteoporosis rather than simply treat established disease using medicines that are well tolerated. We believe that a future humanized monoclonal antibody to FSH is likely to be safer than existing treatments because it will not reside in the bone."

The National Institutes of Health, the U.S. Department of Veterans Affairs, and the U.S. Department of Agriculture supported the research.

Other senior Mount Sinai researchers involved in the study were Terry F. Davies, MD, Li Sun, MD, and Maria New, MD.

Researchers at the Mount Sinai Bone Program have made groundbreaking discoveries in understanding bone remodeling and developing new treatments for osteoporosis, estimated to affect 50 million women worldwide. Recently, the group has discovered the pituitary bone axis, which has revolutionized the paradigm for understanding osteoporosis.

The Mount Sinai Bone Program was established in 1999 with Dr. Zaidi as its Founding Director. It is recognized nationally and internationally for its cutting-edge translational research and highly sought after clinical work in osteoporosis and other bone diseases, including rare genetic diseases, such as Gaucher Disease. It is supported by the National Institutes of Health.


Story Source:

The above story is based on materials provided by Mount Sinai Medical Center. Note: Materials may be edited for content and length.


Journal Reference:

  1. Ling-Ling Zhu, Harry Blair, Jay Cao, Tony Yuen, Rauf Latif, Lida Guo, Irina L. Tourkova, Jianhua Li, Terry F. Davies, Li Sun, Zhuan Bian, Clifford Rosen, Alberta Zallone, Maria I. New, and Mone Zaidi. Blocking antibody to the β-subunit of FSH prevents bone loss by inhibiting bone resorption and stimulating bone synthesis. Proceedings of the National Academy of Sciences, August 20, 2012 DOI: 10.1073/pnas.1212806109

Cite This Page:

Mount Sinai Medical Center. "Dual action polyclonal antibody may offer more effective, safer protection against osteoporosis." ScienceDaily. ScienceDaily, 20 August 2012. <www.sciencedaily.com/releases/2012/08/120820152058.htm>.
Mount Sinai Medical Center. (2012, August 20). Dual action polyclonal antibody may offer more effective, safer protection against osteoporosis. ScienceDaily. Retrieved November 23, 2014 from www.sciencedaily.com/releases/2012/08/120820152058.htm
Mount Sinai Medical Center. "Dual action polyclonal antibody may offer more effective, safer protection against osteoporosis." ScienceDaily. www.sciencedaily.com/releases/2012/08/120820152058.htm (accessed November 23, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Sunday, November 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola-Hit Sierra Leone's Late Cocoa Leaves Bitter Taste

Ebola-Hit Sierra Leone's Late Cocoa Leaves Bitter Taste

AFP (Nov. 23, 2014) The arable district of Kenema in Sierra Leone -- at the centre of the Ebola outbreak in May -- has been under quarantine for three months as the cocoa harvest comes in. Duration: 01:32 Video provided by AFP
Powered by NewsLook.com
Don't Fall For Flu Shot Myths

Don't Fall For Flu Shot Myths

Newsy (Nov. 23, 2014) Misconceptions abound when it comes to your annual flu shot. Medical experts say most people older than 6 months should get the shot. Video provided by Newsy
Powered by NewsLook.com
WFP: Ebola Risks Heightened Among Women Throughout Africa

WFP: Ebola Risks Heightened Among Women Throughout Africa

AFP (Nov. 21, 2014) Having children has always been a frightening prospect in Sierra Leone, the world's most dangerous place to give birth, but Ebola has presented an alarming new threat for expectant mothers. Duration: 00:37 Video provided by AFP
Powered by NewsLook.com
Could Your Genes Be The Reason You're Single?

Could Your Genes Be The Reason You're Single?

Newsy (Nov. 21, 2014) Researchers in Beijing discovered a gene called 5-HTA1, and carriers are reportedly 20 percent more likely to be single. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins